Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Amgen to File NDA for AMG531 in Early 2010
December 7, 2009
- Afinitor, Abraxan Recommended for Approval
December 7, 2009
- Janssen Signs Clinical Research Aid Agreement with Keio Univ.
December 7, 2009
- Chuikyo to Decide on Industry Proposed Drug Pricing System Reform by Year-End
December 7, 2009
- Subanalysis Shows Greater Efficacy for Ticagrelor over Clopidogrel: AZ
December 7, 2009
- Cut Total Medical Fees by 3%: MOF
December 7, 2009
- Roche's GLYT-1 Inhibitor Improves Negative Symptoms of Schizophrenia
December 7, 2009
- Over 100 DPJ Legislators Get Together Calling for Increases in Medical Fees
December 7, 2009
- Korosho to Create Team to Discuss How to Promote Development of Cutting-Edge Technology
December 7, 2009
- Astellas Aims at Well-Balanced Growth in 4 Regions: Mr Nogimori
December 7, 2009
- Takepron Applied for Prevention of Ulcers due to NSAIDs
December 7, 2009
- Nouvelle Place Begins Senior Contract MRs Dispatching Business
December 7, 2009
- Many Patients with Depression Need Treatment for Pain: Dr Shimodera
December 7, 2009
- Glufast Approved in China: Kissei
December 7, 2009
- Switch OTC Recommended for Loxoprofen
December 7, 2009
- Japan Should Establish National Vaccine Plan: Mr Feliciano
December 7, 2009
- Abilify Approved for Irritability in Children with Autistic Disorders in US
December 7, 2009
- Ketotifen Nasal Drops Reclassified as Class 2 OTC Drug
December 7, 2009
- Diovan Back to Top Place on GP Market: Rep Track Survey
December 7, 2009
- Eisai Applies for Aricept Extended-Release Tablets in US
December 7, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…